Current state of therapeutic strategies with ranibizumab in neovascular age-related macular degeneration

Current Opinion in Ophthalmology
Roberto Gallego-PinazoAlfredo García-Layana

Abstract

To summarize the current dosing strategies in the management of neovascular age-related macular degeneration with intravitreal injections of ranibizumab. A variety of therapeutic strategies has been recently described as an alternative to the monthly fixed treatment. The efficacy and local and systemic safety results of each approach is relevant in order to make a clinical decision and to provide patients an accurate information. The proposed therapeutic strategies achieve positive visual outcomes when compared with monthly fixed regimen in the clinical trials. However, the real-life practice does not reflect these results. The main cause of this difference is the incapability to adopt any of the different strategies as the clinics are completely booked and this turns into a delay in the diagnostic and treatment visits.

References

Apr 14, 2004·Archives of Ophthalmology·Nathan CongdonUNKNOWN Eye Diseases Prevalence Research Group
Oct 6, 2006·The New England Journal of Medicine·Philip J RosenfeldUNKNOWN MARINA Study Group
Oct 6, 2006·The New England Journal of Medicine·David M BrownUNKNOWN ANCHOR Study Group
Mar 28, 2007·American Journal of Ophthalmology·Richard Spaide
Nov 21, 2007·Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie·Hussein HollandsJeffery Gale
Jun 12, 2009·Retina·Sharon D SolomonUNKNOWN SST research group and the SST adverse event review committee
Mar 10, 2010·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Shaker A Mousa, Shaymaa S Mousa
Aug 10, 2010·The British Journal of Ophthalmology·Bhaskar GuptaSobha Sivaprasad
Sep 25, 2010·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Philipp Sebastian MuetherSascha Fauser
Dec 21, 2010·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·E Matthé, D Sandner
Aug 9, 2011·Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift für Augenheilkunde·Rufino SilvaJ R Faria de Abreu
Nov 30, 2011·Ophthalmic Research·Elena Prokofyeva, Eberhart Zrenner
Dec 6, 2011·Survey of Ophthalmology·João M FurtadoJuan C Silva
Apr 25, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Jordi MonésRicardo Casaroli-Marano
May 5, 2012·Ophthalmology·UNKNOWN Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupFrederick L Ferris
Jun 27, 2012·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·Irmela MantelAude Ambresin
Oct 23, 2012·Ophthalmology·Jeffrey S HeierUNKNOWN VIEW 1 and VIEW 2 Study Groups
Oct 3, 2013·Ophthalmology·Juan E GrunwaldUNKNOWN CATT Research Group
Jan 11, 2014·Current Opinion in Ophthalmology·Jeffrey R SooHooMalik Y Kahook
May 31, 2014·JAMA Ophthalmology·Gui-shuang YingUNKNOWN CATT Research Group

❮ Previous
Next ❯

Software Mentioned

LUMINOUS
EXCITE

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.